BioCentury
ARTICLE | Company News

Merck, Complix in cancer discovery deal

January 7, 2016 1:32 AM UTC

Complix N.V. (Diepenbeek, Belgium) partnered with Merck & Co. Inc. (NYSE:MRK) to develop Cell-Penetrating Alphabodies (CPABs) against up to two undisclosed intracellular cancer targets.

Complix said it is eligible for $280 million, including an undisclosed upfront payment and milestones, plus tiered royalties. Merck declined to discuss details of the deal, and Complix did not respond to an inquiry. ...